



# NANS2025 ANNUAL MEETING

JANUARY 30 – FEBRUARY 1, 2025 | ORLANDO, FL

CALL FOR  
ABSTRACTS

## NANS 2025 Call for Abstracts

The North American Neuromodulation Society (NANS) invites physicians, allied health professionals, researchers, scientific investigators of all levels to submit an abstract for the 2025 Annual Meeting.

The educational program for the 2025 NANS Annual Meeting will include the presentation of scientific data as Oral Presentations, Paper Poster Presentations, and E-posters. Abstracts submitted for the 2025 NANS Annual Meeting will go through a blind review process, by an independent scientific review committee and scored on scientific merit, originality, relevance to the field of neuromodulation. Although scientific data is important, the quality of the abstract is the primary determinant for acceptance by the NANS Scientific Program Committee.

### **Abstract Topics and Subtopics**

Abstract submitters selecting Scientific Abstract or Case Reports/Small Series will need to select a topic and sub-topic. Below are the descriptions and list of topics and sub-topics.

- **Case Reports/Small Series**
  - This category will only be accepted for a Paper Poster Presentation or an E-poster.
- **Late-Breaking Abstracts**
  - **Only clinical trials will be considered for the Late-Breaking Abstract category.**
    - Abstract submission must be a prospective randomized controlled trial study.
    - The study must be ongoing at the time of the initial submission. Expect to have finalized data **by Thursday, October 24, 2024.**
- **Advocacy and Ethics**
  - Industry Relationship
  - Conflict of Interest
  - Education
  - Pediatric Neuromodulation
  - Diversity
  - Other
- **Basic Science**
- **Brain**
  - Non-Invasive

- Pain – Headache, DBS for other indication
- Epilepsy
- Movement Disorders
- Psychiatric
- Rehabilitation
- ⊖ Computer Interface
- New Indications
- ICV Drugs
- Other
- **Nerve**
  - Headache
  - Genitourinary
  - GI
  - Pain
  - Systematic Disorder (RA, etc.)
  - Other
- **Neural Engineering**
  - Devices (Design and Features)
  - Bio Interfaces
  - Neuroprosthetics
  - Software and Security
  - AI
  - Newer Technologies
  - Other
- **Socioeconomics**
  - Practice Management (reimburse-build)
  - Malpractice
  - Access
  - Contract Negotiation
  - Other
- **Spine**
  - Pain
  - IDDS
  - Spasticity
  - Cardiovascular
  - Restoration
  - New Indication (Parkinson's Disease)
  - Other
- **Other**

## **Duplicate Abstracts**

**If the same abstract is submitted more than once for the 2025 Annual Meeting, then all versions of the abstract will be subject to automatic rejection.** Also, duplicate submissions under **separate categories** will be subject to automatic rejection as well.

For example, do not submit the same abstract under the Late-Breaking Abstract category and the Scientific Abstract category. **To avoid more than one submission of the same abstract, please make sure all authors agree on only one abstract submitter.**

Previously presented or published material should not be submitted.

## **Presentation Formats**

Submitters may indicate their preferred presentation format, but the assigned format is at the discretion of the Scientific Program Committee and Abstract Chairs.

Formats include the following:

- **Oral Presentation:** The highest rated abstracts are selected for an Oral Presentation in a Concurrent Session. The highest-ranked Late Breaking Abstracts are selected for an Oral Presentation. Oral presentations are awarded continuing medical education (CME) credits.
  - In accordance with the [ACCME Standards for Integrity and Independence in Accredited Continuing Education](#) the Presenting Author of an accepted abstract for an Oral Presentation cannot be an [owner or employee of an ACCME-defined ineligible company](#).
  - **Owners:** are defined as individuals who have an ownership interest in a company, except for stockholders of publicly traded companies or holders of shares through a pension or mutual fund.
  - **Employees:** are defined as individuals hired to work for another person or business (the employer) for compensation and who are subject to the employer's direction as to the details of how to perform the job.
  - **Ineligible Company(ies) is/are defined by ACCME)** as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include:
    - Advertising, marketing, or communication firms whose clients are ineligible companies
    - Bio-medical startups that have begun a governmental regulatory approval process

- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
- **Abstract submitters must make sure that the author they designate as the Presenting Author is not an owner or employee of an ineligible company.**
- Paper Poster: Highly-ranked abstracts accepted for Paper Poster Presentation will present their work on individually assigned poster boards during the interactive poster session.
  - The Presenting Author of an abstract accepted for a Paper Poster Presentation is responsible for printing the poster and bringing it with them to the meeting.
  - The Paper Poster Presentation is a non-CME session.
- E-posters: Some abstracts will only receive an acceptance or an Electronic Poster (E-poster). However, all accepted abstracts are required to submit an E-poster to be included in meeting publications.
  - There will not be moderated sessions or physical E-posters during the meeting. E-posters are available during the entirety of the 2025 NANS Annual Meeting in the meeting app. E-posters are non-CME.
- All accepted abstracts will be published electronically following the meeting.

### **Abstract Roles**

- **Abstract Organizer**: This role should be selected if you are an individual submitting the abstract **on behalf** of the Presenting Author and Co-Authors. **Please note: this role is not an author of the abstract. Any name assigned to this role will not be published or listed anywhere as an author of the abstract.**
  - **Example**: Mr. Smith works for company X and needs to submit multiple abstracts on behalf of Dr. Jones; et al. Mr. Smith completes the abstract submission form and “Faculty task” in the abstract submission. Since Mr. Smith is not a Presenting Author or co-author, his role will be “Abstract Organizer. Mr. Smith can then add the

Presenting Author and each Co-Author to the abstract. As an Abstract Organizer, Mr. Smith's name will not be published as an author on meeting materials.

- **Presenting Author:** This role is the individual who will present the accepted abstract at the Annual Meeting. After the abstract is accepted the Presenting Author will be the primary contact for the abstract. All abstracts must have a Presenting Author designated in order to complete the submission. Presenting Authors are responsible for E-Poster submission and printing costs if accepted for paper posters.
  - As noted, under the Oral Presentation format, in accordance with the [ACCME Standards for Integrity and Independence in Accredited Continuing Education](#) the Presenting Author of an accepted abstract for an Oral Presentation cannot be an [owner or employee of an ACCME-defined ineligible company](#). After submission of the abstract the Presenting Author will receive an email along with the submitter.
  
- **Co-Authors:** Each abstract can have a maximum of 25 co-authors. Full names with credentials, contact information, city, and state or country must be included for all authors. **It is imperative that the email addresses for all authors are correct.**

### **Submission Criteria and Considerations for All Abstracts**

- **Title:** The title of the abstract will be published in meeting materials. **Please use title case formatting.**
  - Example of correct formatting: “Programming Optimization Strategies for Burst May Improve Outcomes”.
  
- **Abstract Body:** The abstract body should include an Introduction, Methods, Results, and Conclusion.
  
- **Length of Abstract:** Should not exceed 400 words.
  
- **References:** Include any references that were used in preparing the abstract.
  
- **Figures:** Charts, graphs, or images can be submitted.
  
- **Keywords:** You will need to provide four keywords that describe your abstract.
  
- **Disclosure:** The Abstract Organizer and Presenting Author must complete a disclosure form, listing all financial relationships between themselves and ACCME-defined ineligible companies for the previous 24- months.
  
- **Terms and Conditions:** The Abstract Submitter must review and accept the “Terms and Conditions” for the abstracts.
  
- **CME requirements:** Abstracts accepted for the 2025 NANS Annual Meeting cannot contain advertising, logos, trade names, or a product group message. To ensure all

scientific content is free from commercial bias, please include generic names or terms in your abstract content. If the abstract includes trade names, then names from several companies should be used to present all treatment options.

- **Review Work:** All abstract details, including author information will be published exactly as submitted, **without exception**. Please review submissions carefully for typographical errors.
  - **Once your abstract has been submitted, the NANS Staff is not responsible for making any edits/or changes on your behalf.**
  - Abstract Submitters may make corrections to abstracts **until Thursday, August 15, 2024, at 1:00 PM Central Time**. Data for abstracts cannot be changed after the abstract submission site has closed. NANS Staff will not be able to make any edits/and or changes once the submission site has closed.
- A confirmation email will be sent to the Abstract Organizer and Presenting Author after the successful submission of the abstract.
- **Meeting Expenses:** All abstract presenters, including those who are only accepted for an E-Poster, are responsible for all their own expenses associated with attending the Annual Meeting, including meeting registration, travel, housing, and paper poster printing (if the abstract has been selected for the Paper Poster Session).

### **Late Breaking Abstracts: Guidelines and Submission Requirements**

- To be considered for a Late-Breaking Abstract submission, submitters must submit an initial abstract in the 2025 NANS Annual Meeting Submission System by the submission deadline: Thursday, August 15, 2024. Late submission will not be accepted. There will be NO EXCEPTIONS.
- Submissions are limited to highly significant and timely new and novel research that is unavailable by the original 2025 NANS Annual Meeting abstract submission deadline.
- Late-Breaking Abstracts must not have been submitted, presented, accepted for a presentation, or published in any other scientific venue.
- **Authors may only submit one (1) Late-Breaking Abstract.**
- Duplicate abstracts (reporting the same data) that are not submitted under a different author or abstract category will not be considered.
- **Case studies and case reports CANNOT be submitted as Late-Breaking Abstracts.**
- Late-Breaking Abstracts will be published exactly as they are submitted with no exceptions.
- Submitted Late-Breaking Abstracts will be reviewed by NANS abstract reviewers.
- The highest-ranked Late Breaking Abstracts will be selected for an Oral Presentation in sessions that are awarded CME credits.
  - In accordance with the [ACCME Standards for Integrity and Independence in Accredited Continuing Education](#) the Presenting Author of an accepted Late-

Breaking Abstract cannot be an [owner or employee of an ACCME-defined ineligible company](#).

- **Owners:** are defined as individuals who have an ownership interest in a company, except for stockholders of publicly traded companies or holders of shares through a pension or mutual fund.
  - **Employees:** are defined as individuals hired to work for another person or business (the employer) for compensation and who are subject to the employer's direction as to the details of how to perform the job.
  - **Ineligible Company(ies) is/are defined by ACCME** as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include:
    - Advertising, marketing, or communication firms whose clients are ineligible companies
    - Bio-medical startups that have begun a governmental regulatory approval process
    - Compounding pharmacies that manufacture proprietary compounds
    - Device manufacturers or distributors
    - Diagnostic labs that sell proprietary products
    - Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
    - Manufacturers of health-related wearable products
    - Pharmaceutical companies or distributors
    - Pharmacy benefit managers
    - Reagent manufacturers or sellers
  - **Late-Breaking Abstract Submitters must make sure that the author they designate as the Presenting Author [is not an owner or employee of an ineligible company](#).**
- If selected for consideration, Late-Breaking Abstract submission, submitters will receive a notification from NANS staff in early October to submit updated data.
  - Submitters will be required to submit updated data **by Thursday, October 24, 2024**. Late submissions will not be accepted. There will be NO EXCEPTIONS.
  - Late-Breaking Abstract acceptance notifications will be sent via email to the Presenting Author in late November 2024.

- If selected, the Presenting Author designated by the submitter during the submission process will be responsible for all expenses associated with attending the Annual Meeting, including meeting registration, travel, and housing.

### **Accessing an Abstract After the NANS Abstract Submission Site is Closed**

After the submission site is closed, only the Abstract Organizer will be able to log in to the submission site and see a “read-only” version of the abstract submission. It is highly encouraged to print or save a copy of your abstract submission before the submission site closes.

### **Questions?**

Please contact Kim Stamp, NANS Education Coordinator at [kstamp@neuromodulation.org](mailto:kstamp@neuromodulation.org) .